{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T09:48:34Z","timestamp":1771667314005,"version":"3.50.1"},"reference-count":22,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2010,9,2]],"date-time":"2010-09-02T00:00:00Z","timestamp":1283385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> High\u2010potency topical and perilesional\/intralesional corticosteroids are becoming increasingly useful as adjuvant to treat autoimmune blistering diseases.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> We sought to evaluate the role of perilesional\/intralesional triamcinolone acetonide (PITA) injections in reducing the time for first complete clinical remission and the total amount of systemic corticosteroids in oro\u2010pharyngeal pemphigus vulgaris (OPV) patients, and also the compliance of PITA injections, in terms of satisfaction, pain and discomfort.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Thirty\u2010five OPV patients were treated with conventional immunosuppressive therapy (CIST) and received high potency topical corticosteroids (clobetasol and\/or methylprednisolone) and\/or PITA injections. Patients were grouped as follows: (i) a group of 16 patients was treated with PITA injections and (ii) a group of 19 patients without PITA injections.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Sixteen patients treated with PITA injections and 19 without PITA injections reached complete clinical remission within 126.6\u2003days (SD: 41; 95% CI: 104.7\u2013148.8) and 153.2\u2003days (SD: 97.4; 95% CI: 106.2\u2013200.1) (<jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.4) respectively. The total amount of corticosteroids in patients treated with PITA and without PITA was 4894\u2003mg (SD: 2832; 95% CI: 3385\u20136403) and 5312\u2003mg (SD: 4009; 95% CI: 3380\u20137245) (<jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.4) respectively. Patients treated with PITA reported a satisfaction score significantly higher than pain (<jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.0007) and discomfort score (<jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.0006).<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Perilesional\/intralesional triamcinolone acetonide injections seems to represent a helpful clinical tool to successfully join CIST, in terms of shortening the time of complete clinical remission, reducing the total amount of corticosteroids and obtaining an acceptable compliance.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2010.03610.x","type":"journal-article","created":{"date-parts":[[2010,3,5]],"date-time":"2010-03-05T06:41:07Z","timestamp":1267771267000},"page":"1157-1165","source":"Crossref","is-referenced-by-count":28,"title":["Adjuvant triamcinolone acetonide injections in oro\u2010pharyngeal pemphigus vulgaris"],"prefix":"10.1111","volume":"24","author":[{"given":"MD","family":"Mignogna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Fortuna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Leuci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Dell\u2019Aversana Orabona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Ruoppo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,9,2]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02825.x"},{"key":"e_1_2_7_3_2","first-page":"CD006263","article-title":"Interventions for pemphigus vulgaris and pemphigus foliaceus","author":"Martin LK","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0030-4220(94)90318-2"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66829-8"},{"key":"e_1_2_7_6_2","first-page":"268","article-title":"Current therapy of pemphigus vulgaris","volume":"68","author":"Fellner MJ","year":"2001","journal-title":"Mt Sinai J Med"},{"key":"e_1_2_7_7_2","first-page":"410","article-title":"Treatment of pemphigus and pemphigoids","volume":"10","author":"Lopez\u2010Jornet P","year":"2005","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(00)90213-5"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.01.012"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0714.2000.290401.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(03)02738-5"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2702.2005.01121.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1980.01640320048012"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0030-4220(91)90300-2"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1079-2104(97)90030-5"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02895.x"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70476-1"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2004.01499.x"},{"key":"e_1_2_7_19_2","first-page":"142","article-title":"Topical tacrolimus: a novel therapeutic intervention for recalcitrant labial pemphigus vulgaris","volume":"13","author":"Hodgson TA","year":"2003","journal-title":"Eur J Dermatol"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1902\/jop.2005.76.1.154"},{"key":"e_1_2_7_21_2","first-page":"667","article-title":"Pemphigus vulgaris: a case\u2010based update","volume":"71","author":"Ben Lagha N","year":"2005","journal-title":"J Can Dent Assoc"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2005.31216"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2005.076190"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2010.03610.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2010.03610.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T08:47:43Z","timestamp":1697359663000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2010.03610.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,2]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1468-3083.2010.03610.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2010.03610.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,2]]}}}